Low-fat, high fruit and vegetable diets and weight loss do not affect biomarkers of cellular proliferation in Barrett esophagus

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 10, 2005, Pages 2377-2383

  Kristal, Alan R ^a,b   Blount, Patricia L ^a,b   Schenk, Jeannette M ^a,b   Sanchez, Carissa A ^a   Rabinovitch, Peter S ^b   Odze, Robert D ^c   Standley, Judi ^a   Vaughan, Thomas L ^a,b   Reid, Brian J ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; BIOLOGICAL MARKER; DNA; KI 67 ANTIGEN;

ACADEMIC ACHIEVEMENT; ALCOHOL CONSUMPTION; ANEUPLOIDY; ANTHROPOMETRY; ARTICLE; BARRETT ESOPHAGUS; BODY MASS; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EPITHELIZATION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS BIOPSY; ETHNOLOGY; FEMALE; FLOW CYTOMETRY; FRUIT; GASTROESOPHAGEAL REFLUX; HIGH FIBER DIET; HUMAN; HUMAN TISSUE; INCOME; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MARRIAGE; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SMOKING; STATISTICAL ANALYSIS; TETRAPLOIDY; VEGETABLE; WEIGHT REDUCTION;

ADENOCARCINOMA; BARRETT ESOPHAGUS; BIOLOGICAL MARKERS; DIETARY FATS; ESOPHAGEAL NEOPLASMS; FEMALE; FRUIT; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; VEGETABLES; WEIGHT LOSS;

EID: 26444516632     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0158     Document Type: Article

References (52)

1. Sampliner R. The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's esophagus. Am J Enterol 2002;97:1888-95.
2. Levine DS. Barrett's esophagus. Sci Amer Sci and Med 1994;1:16-25.
3. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting or cancer risk in Barrett's esophagus? Gastroenterology 2000;119:333-8.
4. Jankowski J, Provenzale D, Moayyedi P. Oesophageal adenocarcinoma arising from Barrett's metaplasia has regional variations in the West. Gastroenterology 2002;122:588-90.
5. Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 2002;11:236-56.
6. Devesa SS, Blot WJ, Fraumeni JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-53.
7. Younes M, Henson DE, Ertan A, Miller CC. Incidence and survival trends of esophageal carcinoma in the United States: racial and gender differences by histological type. Scand J Gastroenterol 2002;37:1359-65.
8. Mayne ST, Navarro SA. Diet, obesity and reflux in the etiology of adenocarcinomas of the esophagus and gastric cardia in humans. J Nutr 2002;132:3467-70S.
9. Mayne ST, Risch HA, Dubrow R, et al. Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 2001;10:1055-62.
10. Vaughan TL, Davis S, Kristal AR, Thomas DB. Obesity, alcohol and tobacco as risk factors for cancer of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 1995;4:85-92.
11. Meining A, Classen M. The role of diet and lifestyle measures in the pathogenesis and treatment of gastroesophageal reflux disease. Am J Enterol 2000;95:2692-7.
12. Chow WH, Blot WJ, Vaughan TL, et al. Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst 1998;90:150-5.
13. Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 1998;7:97-102.
14. Vaughan TL, Kristal AR, Blount PL, et al. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2002;11:745-52.
15. Corley DA, Kerlikowske KBPA. Protective association of aspirin/NSAIDs and esophageal cancer: a meta-analysis. Gastroenterology 2003;124:47-56.
16. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline history and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76.
17. Moe GL, Kristal AR, Levine DS, Vaughan TL, Reid BJ. Waist to hip ratio, weight gain, and dietary and serum selenium are associated with DNA content flow cytometry in Barrett's esophagus. Nutr Cancer 2000;36:7-13.
18. Levine DS, Haggitt RC, Blount PL, Rabinovitch PS, Rusch VW, Reid BJ. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993;105:40-50.
19. Kristal AR, Shattuck AL, Bowen DJ, Sponzo RW, Nixon DW. Feasibility of using volunteer research staff to deliver and evaluate a low-fat dietary intervention: the American Cancer Society Breast Cancer Dietary Intervention Project. Cancer Epidemiol Biomarkers Prev 1997;6:459-67.
20. Levine DS, Reid BJ. Endoscopic biopsy technique for acquiring larger mucosal samples. Gastrointest Endosc 1991;37:332-7.
21. Reid BJ, Blount PL, Rubin CE, Levine DS, Haggitt RC, Rabinovitch PS. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102:1212-9.
22. Reid BJ, Sanchez CA, Blount PL, Levine DS. Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. 1993;105:119-29.
23. Patterson RE, Kristal AR, Carter RA, Fels-Tinker L, Bolton MP, Agurs-Collins T. Measurement characteristics of the Women's Health Initiative food frequency questionnaire. Ann Epidemiol 1999;9:178-87.
24. Kristal AR, Shattuck AL, Williams AE. Food frequency questionnaires for diet intervention research. 17th National Nutrient Databank Conference. Baltimore (MD): International Life Sciences Institute; 1992. pp. 110-25.
25. Feshkanish D, Sielaff BH, Chong K. Computerized collection and analysis of dietary intake information. Comput Methods Programs Biomed 1989;30:47-57.
26. Brown LM, Swanson CA, Gridley G, Swanson GM, Schoenberg JB, Greenberg RS. Adenocarcinoma of the esophagus: role of obesity and diet. J Natl Cancer Inst 1995;87:104-9.
27. Chen H, Tucker KL, Graubard BI, et al. Nutrient intakes and adenocarcinoma of the esophagus and distal stomach. Nutr Cancer 2002;42:33-40.
28. Zhang ZF, Kurtz RC, Yu GP, et al. Adenocarcinomas of the esophagus and gastric cardia: the role of diet. Nutr Cancer 1997;27:298-309.
29. Tzonou A, Lipworth L, Garidou A, et al. Diet and risk of esophageal cancer by histologic type in a low-risk population. Int J Cancer 1996;68:300-4.
30. Kabat GC, Ng SKC, Wynder EL. Tobacco, alcohol intake, and diet in relation to adenocarcinoma of the esophagus and gastric cardia. Cancer Causes Control 1993;4:123-32.
31. Chen H, Ward MH, Graubard BI, et al. Dietary patterns and adenocarcinoma of the esophagus and distal stomach. Am J Clin Nutr 2002;75:137-44.
32. Engel LS, Chow W-H, Vaughan TL, et al. Population attributable risks of esophageal and gastric cancers. Int J Cancer 2003;95:1404-13.
33. Terry PD, Lagergren J, Hansen H, Wolk A, Nyrén O. Fruit and vegetable consumption in the prevention of oesophageal and cardia cancers. Eur J Cancer Prev 2001;10:365-9.
34. Lagergren J, Bergström R, Nyrén O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999;130:883-90.
35. Caygill CPJ, Johnston DA, Lopez M, et al. Lifestyle factors and Barrett's esophagus. Am J Enterol 2002;97:1328-31.
36. Li SD, Mobarhan S. Association between body mass index and adenocarcinoma of the esophagus and gastric cardia. Nutr Rev 2000;58:54-9.
37. Kitchin LI, Castell DO. Rationale and efficacy of conservative therapy for gastroesophageal reflux disease. Arch Intern Med 1991;151:448-54.
38. Mercer CD, Wren SF, DaCosta LR. Gastroesophageal pressure gradients and lower esophageal sphincter pressures on severely obese patients. Gastroenterology 1982;82:1129.
39. Ruhl CE, Everhart JE. Overweight, but not high dietary fat intake, increases risk of gastroesophageal reflux disease hospitalization: the NHANES I Epidemiologic Follow-up Study. Ann Epidemiol 1999;9:424-35.
40. Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. Risk factors associated with symptoms of gastroesophageal reflux. Am J Med 1999;106:642-9.
41. Nilsson MJR, Ye W, Hveem K, Lagergren J. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA 2003;290:66-72.
42. Murray L, Johnston B, Lane A, et al. Relationship between body mass and gastro-oesophageal reflux symptoms: the Bristol Helicobacter Project. Int J Epidemiol 2003;32:645-50.
43. Mirvish SS, Huang Q, Chen SC, et al. Metabolism of carcinogenic nitrosamines in the rat and human esophagus and induction of esophageal adenocarcinoma in rats. Endoscopy 1993;25:627-31.
44. Clark GW, Smyrk TC, Mirvish SS, et al. Effect of gastroduodenal juice and dietary fat on the development of Barrett's esophagus and esophageal neoplasia: an experimental rat model. Ann Surg Oncol 1994;1:252-61.
45. Penagini R, Mangano M, Bianchi PA. Effect of increasing the fat content but not the energy load of a meal on gastro-oesophageal reflux and lower oesophageal sphincter motor function. Gut 1998;42:330-3.
46. Pehl C, Waizenhoefer A, Wendl B, Schmidt T, Schepp W, Pfeiffer A. Effect of low and high fat meals on lower esophageal sphincter motility and gastroesophageal reflux in healthy subjects. Am J Gastroenterol 1999;94:1192-6.
47. Becker DJ, Sinclair J, Castell DO, Wu WC. A comparison of high and low fat meals on postprandial esophageal acid exposure. Am J Gastroenterol 1989;84:782-6.
48. Colombo P, Mangano M, Bianchi PA, Penagini R. Effect of calories and fat on postprandial gastro-oesophageal reflux. Scand J Gastroenterol 2002;37:3-5.
49. Bowen D, Clifford CK, Coates R, et al. The Women's Health Trial Feasibility Study in Minority Populations: design and baseline descriptions. Ann Epidemiol 1996;6:507-19.
50. Coates RJ, Bowen DJ, Kristal AR, et al. The Women's Health Trial Feasibility Study in Minority Populations: changes in dietary intakes. Am J Epidemiol 1999;149:1104-12.
51. Wong DJ, Paulson TG, Prevo LJ, et al. p16INK4a lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001;61:8284-9.
52. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk of disease progression. Am J Gastroenterol 2001;96:2839-48.